Cargando…

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

BACKGROUND: The mixed-lineage leukemia (MLL) gene is located on chromosome 11q23. The MLL gene can be rearranged to generate partial tandem duplications (MLL-PTD), which occurs in about 5-10% of acute myeloid leukemia (AML) with a normal karyotype and in 5-6% of myelodysplastic syndrome (MDS) patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Jun, Gao, Meng-Ge, Qin, Ya-Zhen, Wang, Yu, Yan, Chen-Hua, Sun, Yu-Qian, Chang, Ying-Jun, Xu, Lan-Ping, Zhang, Xiao-Hui, Liu, Kai-Yan, Huang, Xiao-Jun, Zhao, Xiao-Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721994/ https://www.ncbi.nlm.nih.gov/pubmed/34979982 http://dx.doi.org/10.1186/s12885-021-09051-5

Ejemplares similares

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
por: Sun, Q-Y, et al.
Publicado: (2017)

Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Jing, et al.
Publicado: (2018)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
por: Burmeister, Thomas, et al.
Publicado: (2012)

Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia
por: Bai, Lu, et al.
Publicado: (2022)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Pan, Jonathan, et al.
Publicado: (2020)

Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia
por: Gao, Li, et al.
Publicado: (2016)

MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report
por: He, Zhipeng, et al.
Publicado: (2018)

The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements
por: Yang, Hua, et al.
Publicado: (2016)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
por: Du, Zhi zhuo, et al.
Publicado: (2022)

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis
por: Fan, Shuang, et al.
Publicado: (2023)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2017)

PB2447: PREEMPTIVE TREATMENT WITH PD-1 ANTIBODY FOR ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME WITH POSITIVE MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Ling, et al.
Publicado: (2023)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2016)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain
por: Zhang, Shannon, et al.
Publicado: (2019)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
por: Zhu, Xiao-Na, et al.
Publicado: (2023)

Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies
por: Shen, Meng-Zhu, et al.
Publicado: (2022)

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2019)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
por: Verboon, Lonneke J., et al.
Publicado: (2016)

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Kadri, Yasmine, et al.
Publicado: (2022)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

The Differential Expression of CD47 may be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia
por: Yan, Xiao, et al.
Publicado: (2022)

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis
por: Du, Yufeng, et al.
Publicado: (2023)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
por: Grubovikj, Rada M., et al.
Publicado: (2012)

Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2019)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation
por: Cao, Le-Qing, et al.
Publicado: (2021)

Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
por: Cao, Xing-yu, et al.
Publicado: (2023)

KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements
por: Au, Yan Zi, et al.
Publicado: (2021)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice
por: Wang, Hao, et al.
Publicado: (2020)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
por: Oka, Satoko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jqje3uk9a29savdjb2mt4b39d5